Search

Your search keyword '"Akre, Monica K."' showing total 9 results
Start Over Author "Akre, Monica K."
9 results on '"Akre, Monica K."'

8. ALKalterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients

Author

Sukov, William R, Hodge, Jennelle C, Lohse, Christine M, Akre, Monica K, Leibovich, Bradley C, Thompson, R Houston, and Cheville, John C

Abstract

Chromosomal rearrangements involving the anaplastic lymphoma kinase gene (ALK) at 2p23 result in fusion with various partner genes leading to aberrant production of oncogenic protein products in multiple tumor types. Recently, the ALK protein inhibitor crizotinib was shown to be an effective therapy in patients with ALK-rearranged non-small cell lung cancer. The goal of this study was to determine the frequency of ALKalterations in adult renal cell carcinoma (RCC) and define associated clinicopathologic features and outcome. RCCs from a cohort of 534 consecutive surgically treated adult patients were analyzed for alterations of ALKby fluorescence in situhybridization. ALKrearrangements were identified in 2 of 534 (<1%) RCCs. Both showed similar histologic features and the patients had a poor outcome. ALKcopy number gain was identified in 54 (10%) RCCs. In clear cell type RCC (CCRCC), ALKcopy number gain was significantly associated with tumor size (P=0.02) and nuclear grade (P<0.001), and with a worse 10-year cancer-specific survival vssimilar patients lacking ALKcopy number gain (P=0.03). ALKrearrangement is rare in adult RCC but may be associated with distinct histological features and poor outcome. Another potential mechanism to elevate ALK expression, increased ALKgene copy number, was observed in 10% of adult CCRCC, where it is associated with a higher tumor grade and poorer outcome. Additional studies are necessary to determine whether patients RCCs with ALKrearrangement and/or those with an increase in ALKcopy number would benefit from ALK inhibitor treatment.

Published
2012
Full Text
View/download PDF

9. Relationship between a Weighted Multi-Gene Algorithm and Blood Pressure Control in Hypertension.

Author

Phelps, Pamela K., Kelley, Eli F., Walla, Danielle M., Ross, Jennifer K., Simmons, Jerad J., Bulock, Emma K., Ayres, Audrie, Akre, Monica K., Sprissler, Ryan, Olson, Thomas P., and Snyder, Eric M.

Subjects
BLOOD pressure, HYPERTENSION, ALGORITHMS, FAMILY history (Medicine), DRUG therapy
Abstract

Hypertension (HTN) is a complex disease with interactions among multiple organ systems, including the heart, vasculature, and kidney with a strong heritable component. Despite the multifactorial nature of HTN, no clinical guidelines utilize a multi-gene approach to guide blood pressure (BP) therapy. Non-smokers with a family history of HTN were included in the analysis (n = 384; age = 61.0 ± 0.9, 11% non-white). A total of 17 functional genotypes were weighted according to the previous effect size in the literature and entered into an algorithm. Pharmacotherapy was ranked from 1–4 as most to least likely to respond based on the algorithmic assessment of individual patient's genotypes. Three-years of data were assessed at six-month intervals for BP and medication history. There was no difference in BP at diagnosis between groups matching the top drug recommendation using the multi-gene weighted algorithm (n = 92) vs. those who did not match (n = 292). However, from diagnosis to nadir, patients who matched the primary recommendation had a significantly greater drop in BP when compared to patients who did not. Further, the difference between diagnosis to current 1-year average BP was lower in the group that matched the top recommendation. These data suggest an association between a weighted multi-gene algorithm on the BP response to pharmacotherapy. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results